Advances in Inflammatory Bowel Disease
Mary Greeley Medical Center Grand Rounds is a multi-disciplinary clinical activity which serves to maintain, develop, or increase the knowledge, skills, and professional performance and relationships that a physician uses to provide services for patients, the public or the profession.
Physicians, mid-level providers, nurses and healthcare administrators.
- Identify drugs and drug classes used for the medical treatment of Crohn's disease and ulcerative colitis.
- Understand the shift from a reactive, symptom-based treatment paradigm to one that is proactive and based on objective assessment of inflammation.
- Incorporate therapeutic drug monitoring (for thiopurines, infliximab, and adalimumab) into the medical management of patients with Crohn's disease and ulcerative colitis.
Edward Loftus, Jr., MD
Gastroenterology/Hepatology, Mayo Clinic
- Dr. Loftus discloses the following financial relationships: consulting and research support (fees to Mayo Clinic) for Janssen, UCP Pharmaceuticals, AbbVie, and Taheda.
- Dr. Brenda Burrough discloses she is a principal investigator in an Amgen research trial.
- No member of the Mary Greeley Medical Center CME Committee who planned this activity, including Dr. Burrough, has any financial relationship to disclose relating to the content.
This program is supported by gifts to the Mary Greeley Medical Center Foundation from Mary Greeley Medical Center, McFarland Clinic, First American Bank, and Green Hills Health Care Center. The content and selection of speaker(s) is the responsibility of the Mary Greeley Medical Center for Continuing Medical Education Committee and not the sponsors of this program.
Continuing Education Credit
DO: Des Moines University (DMU) is accredited by the American Osteopathic Association to provide osteopathic continuing medical education for physicians. DMU designates this program for a maximum of 1.0 AOA Category 2-A credits and will report CME and specialty credits commensurate with the extent of the physician’s participation in this activity.
- 1.00 AOA Category 2A